Search

Roche Holding AG

Cerrado

SectorSanidad

283.2 -0.07

Resumen

Variación precio

24h

Actual

Mínimo

279.6

Máximo

286

Métricas clave

By Trading Economics

Ingresos

1.7B

3.7B

Ventas

-15B

16B

P/B

Media del Sector

25.123

37.461

Rentabilidad por dividendo

3.28

Margen de beneficios

23.266

Empleados

103,249

EBITDA

547M

6.5B

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.28%

2.33%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

22B

227B

Apertura anterior

283.27

Cierre anterior

283.2

Roche Holding AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 oct 2025, 09:32 UTC

Ganancias

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 oct 2025, 05:54 UTC

Ganancias

Roche Raises Full-Year Earnings Outlook

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

18 sept 2025, 14:01 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

18 sept 2025, 10:05 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

89bio Shares Soar Premarket on Takeover by Roche

18 sept 2025, 10:04 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

18 sept 2025, 05:37 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy 89bio for Up to $3.5 Billion

23 oct 2025, 09:19 UTC

Charlas de Mercado
Ganancias

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 oct 2025, 09:11 UTC

Charlas de Mercado
Ganancias

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 oct 2025, 05:09 UTC

Ganancias

Roche 3Q Sales Up 6% At CER

23 oct 2025, 05:07 UTC

Ganancias

Roche 3Q Sales CHF14.92B

23 oct 2025, 05:07 UTC

Ganancias

Analysts Had Seen 3Q Sales At CHF15.17B

23 oct 2025, 05:07 UTC

Ganancias

Roche See Core Earnings Per Share Growth In High-Single to Low-Double-Digit Range At CER

23 oct 2025, 05:05 UTC

Ganancias

Roche Expects An Increase In Group Sales In Mid-Single-Digit Range At CER

23 oct 2025, 05:04 UTC

Ganancias

Roche: Group Sales Up 7% At Constant Exchange Rates In First Nine Months

23 oct 2025, 05:02 UTC

Ganancias

Roche Had Seen High-Single-Digit 2025 Core Earnings Per Share Growth at CER

23 oct 2025, 05:02 UTC

Ganancias

Roche Had Seen Mid-Single-Digit 2025 Sales Growth At Constant Exchange Rates

23 oct 2025, 05:02 UTC

Ganancias

Roche 9-Mos CH45.9B

23 oct 2025, 05:01 UTC

Ganancias

Roche Raises 2025 View

1 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 oct 2025, 09:05 UTC

Acciones populares

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

18 sept 2025, 14:12 UTC

Adquisiciones, fusiones, absorciones

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

18 sept 2025, 07:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

18 sept 2025, 05:09 UTC

Adquisiciones, fusiones, absorciones

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

18 sept 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Roche: Deal Is Expected to Close in 4Q

18 sept 2025, 05:06 UTC

Adquisiciones, fusiones, absorciones

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

18 sept 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

18 sept 2025, 05:05 UTC

Adquisiciones, fusiones, absorciones

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

18 sept 2025, 05:04 UTC

Adquisiciones, fusiones, absorciones

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

18 sept 2025, 05:03 UTC

Adquisiciones, fusiones, absorciones

Roche: Total Deal Value Is Up to $3.5B

Roche Holding AG previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat